Pharma Intelligence Apps

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Glenmark Debuts Favipiravir For COVID-19 In India

Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Dr Reddys Joins Remdesivir Licensees

Dr Reddy’s has become the latest firm to strike a licensing deal with Gilead for its remdesivir potential treatment for COVID-19.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

WHO Launches COVID-19 Technology Access Pool

C-TAP, the voluntary initiative aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all, has been launched by the WHO, in partnership with Costa Rica.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Teva, Sandoz And Accord Take COVID-19 Action

While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Hikma Outlines Strategy For Coping With COVID-19 Demand

As Hikma launches propofol vials in three presentations in the US to address a local shortage, CEO Siggi Olafsson explains how the company is more broadly keeping on top of the higher demand generated by the coronavirus pandemic.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Teva, Sandoz And Accord Take COVID-19 Action

While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

WHO Launches COVID-19 Technology Access Pool

C-TAP, the voluntary initiative aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all, has been launched by the WHO, in partnership with Costa Rica.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Celltrion Sets Out Plans To Trial Coronavirus Treatments

In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Biosimilars Conference Coverage

Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Celltrion Will Trial COVID-19 Antiviral From July

Celltrion has made progress in finding an effective treatment for COVID-19 by identifying 14 antibodies able to neutralize coronavirus. The company aims to eventually roll out mass production of a therapeutic antibody treatment after starting human trials this July.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Australian Bodies Set Out Joint Position On Coronavirus

Australia’s off-patent industry association, the GBMA, and local brand organization Medicines Australia have set out their plans for collaborating on supplying essential medicines amid the coronavirus pandemic.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Coronavirus Puts The Brakes On Mylan-Upjohn Merger

Mylan and Pfizer’s Upjohn were all set to merge into Viatris by midway through this year, subject to certain approvals, but that will now not happen in that timeframe as the global coronavirus pandemic proves an insurmountable barrier to getting the deal over the line.  

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Australia Relaxes Competition Rules To Facilitate Coronavirus Response

Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Celltrion Makes Progress On Coronavirus Treatment

Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

Biomedtracker: 開発中医薬品をFDA承認確率で評価, Trialtrove: 医療用医薬品の臨床試験情報デ...

COVID-19 Infographic

Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

COVID-19 24-hour web event: Lessons learned and a path forward

Join our free 24-hour interactive webinar series on 21 July that will cover the latest insights and learning on COVID-19 from across the global Pharma and Biomedtech industry.

The “New Normal” for Clinical Research in the Wake of COVID-19

We conducted a survey to 100 clinical trial investigators to gauge expectations for future clinical research. Your free infographic provides key insight and analysis to help you understand the future clinical trial landscape.

Pharma Intelligence Apps, Citeline

Signals Analytics Powers Informa Pharma Intelligence’s Offerings With Next Generation Advanced Analytics

Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, and Signals Analytics, the next generation advanced analytics platform that leverages external data to uncover trends and novel insights, today announced a joint offering that helps life sciences companies to identify new opportunities, mitigate investment risks and accelerate the drug development process.

Adoptive Cell Therapy

Citeline recently introduced a new Therapeutic Class called "Adoptive cell therapy", enabling more granular searching capabilities to hone in on this exciting cancer immunotherapy that is expanding the horizon of personalized medicine

Breast Cancer Clinical Landscape and Recent Trends Whitepaper

Get a deeper understanding of breast cancer clinical trials initiated since 2014 and what the trends have meant for strategies in this area, with this free whitepaper from Citeline.

Citeline

Rescuing The Opioid Crisis

Recent news of the Ohio State ruling on the opioid litigation trial against Johnson & Johnson shed new light on the complex opioid addiction crisis in the US.

The 5th Annual Citeline Awards Return to Boston for Second Year

London – 30 October, 2019 – Informa Pharma Intelligence is pleased to announce that The Citeline Awards (previously known as the CARE Awards) is returning for their second year.  The awards will once again be held in Boston, MA at the Hyatt Regency, on April 30, 2020.

Citeline

Informa Pharma Intelligence and Saama Technologies Develop New AI/Workflow Solutions

LONDON – September 30, 2019 – Informa Pharma Intelligence and Saama Technologies today announced a strategic partnership enabling Informa's Citeline and Saama's Life Science Analytics Cloud (LSAC) customers to apply world-class AI to both Citeline clinical intelligence expertise and real world evidence to design clinical trials which better serve the needs of both the customers and their patients.

Exploring Basket and Umbrella Oncology Trials

To increase flexibility and efficiency in drug development, master protocols have emerged as an innovative clinical trial design, including basket and umbrella trials. Learn more about how these approaches are being used within oncology research through an overview of the clinical landscape, trial outcomes and trends.

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Clinical Trial Design Report

Rising costs, patient recruitment issues, shifting regulations, and more are making bringing new drugs to market more difficult than ever. Explore changes in clinical trial design being adopted in response to these challenges with reporting from Pink Sheet.

Clinical Trials State of the Industry Report 2019

KNect365 Life Sciences recently conducted a survey into the clinical trial industry at its most interesting point to date, as organisations are implementing new technologies and trends such as AI, virtual trials and wearables. The final report, based on 214 responses, reveals unique insights into what current benefits and challenges companies are facing in the processes of applying these new approaches to therapeutic development. Citeline introduces the report, exploring what some of the key takeaways mean for the industry.

Taking the High Out of Pain: Exploring Abuse-Deterrent Opioids and Opioid Alternatives

With opioid abuse and deaths in the US at an all-time high, the journey to battle the opioid epidemic continues – keeping drug companies and the FDA working hard to come up with effective alternatives for pain.

Pharmaprojects: 医薬品開発パイプラインのデータベース

New Active Substances (NAS) LAUNCHED DURING 2018

For a snapshot of the new active substances (NAS) successfully launched last year, download the data-packed New Active Substances (NAS) Launched During 2018 infographic from Citeline.

Sitetrove: 治験責任医師と治験施設情報のデータベース, Trialtrove: 医療用医薬品の臨床試験情報デー...

Citeline: Global Clinical Trial Intelligence Solutions

Citeline is the industry’s most comprehensive, reliable and up-to-date global clinical trial intelligence suite, designed to help you save time and money by enrolling patients faster. Our team of more than 250 industry experts transform data into knowledge, integrating robust drug, trial, investigator, and site intelligence.

Skipta, Citeline

A Nautical but Nice Look at BTK inhibitors for Rheumatoid Arthritis

Skipta, the leading social network of specialized online medical communities for verified healthcare professionals, recently hosted a virtual advisory board session, through its proprietary Skipta Gather technology, asking physicians what they saw as the current unmet needs in the treatment of rheumatoid arthritis (RA).